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Abstract
Background
People with diabetes have a high risk of developing micro- and macrovascular complica-
tions associated with diminished life expectancy and elevated treatment costs. Patient edu-
cation programs can improve diabetes control in the short term, but their cost-effectiveness
is uncertain. Our study aimed to analyze the lifelong cost-effectiveness of a nurse-led tele-
coaching program compared to usual care in people with type 2 diabetes from the perspec-
tive of the Belgian healthcare system.
Methods
The UKPDS Outcomes Model was populated with patient-level data from an 18-month ran-
domized clinical trial in the Belgian primary care sector involving 574 participants; trial data
were extrapolated to 40 years; Quality Adjusted Life Years (QALYs), treatment costs and
Incremental Cost-Effectiveness Ratio (ICER) were calculated for the entire cohort and the
subgroup with poor glycemic control at baseline (“elevated HbA1c subgroup”) and the
associated uncertainty was explored.
Results
The cumulative mean QALY (95% CI) gain was 0.21 (0.13; 0.28) overall and 0.56 (0.43;
0.68) in elevated HbA1c subgroup; the respective incremental costs were €1,147 (188;
2,107) and €2,565 (654; 4,474) and the respective ICERs €5,569 (€677; €15,679) and
€4,615 (1,207; 9,969) per QALY. In the scenario analysis, repeating the intervention for life-
time had the greatest impact on the cost-effectiveness and resulted in the mean ICERs of
€13,034 in the entire cohort and €7,858 in the elevated HbA1c subgroup.
Conclusion
Taking into account reimbursement thresholds applied in West-European countries, nurse-
led telecoaching of people with type 2 diabetes may be considered highly cost-effective
within the Belgian healthcare system.
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Introduction
About 387 million people worldwide have diabetes and its prevalence is expected to increase by
more than 50% in the coming twenty years [1]. People with diabetes have a high risk of devel-
oping cardiovascular disease, kidney failure, neuropathy and retinopathy, that is associated
with diminished life expectancy and health-related quality of life and elevated treatment costs
[2,3]. About 90% of the diabetes population suffers from type 2 diabetes. Appropriate lifestyle
adjustments, medication adherence and regular risk factor control are recommended to
achieve sustainable treatment results in type 2 diabetes [3,4]. Patient education aimed at diabe-
tes self-management optimization has been shown to improve diabetes knowledge, self-efficacy
and risk factor control [5–7]. However, there is less certainty about its cost-effectiveness [8–
10]. The economic evaluations of patient education in type 2 diabetes demonstrated a broad
range of results, from cost-saving to not cost-effective at all, while the quality of the studies as
well as the underlying clinical evidence varied [11]. Further local context-driven high-quality
field research in this area is needed to support policymakers in their choice of appropriate
patient support strategies within the budgetary constraints.
The clinical efficacy and cost-effectiveness of diabetes education has not been previously
assessed in Belgium.Reimbursed diabetes education was initially introduced in Belgium in
1988 in a hospital ambulatory setting for people with advanced diabetes, i.e. those in need of
three or more insulin injections per day. It was extended to primary care in 2009, when “diabe-
tes care trajectories” were launched. Diabetes care trajectories imply that when insulin therapy
needs to be initiated, patients are entitled to multidisciplinary care that includes education
from a certifieddiabetes educator and an annual consultation with an endocrinologist, in addi-
tion to the regular GP visits. In primary care, diabetes education is mostly delivered in individ-
ual face-to-face sessions at the patient’s home and focusesmainly on training in self-
administration of insulin and analogues.Most of the non-insulin-dependent patients are cur-
rently not offered structured self-management support programs. As individual face-to-face
education is costly, alternative deliverymodes need to be tested. Telecoaching delivers empow-
erment and remote support using information and communication technologies. It has the
potential to ensure better patient inclusion in diabetes education, while keeping down nurse
and patient transport costs.
In 2012, the Independent Health Insurance Fund of Belgium set up a pragmatic randomized
clinical trial to investigate the effect of nurse-led telecoaching on diabetes risk factor control
among its affiliates with type 2 diabetes. Their claims data were used for the economic evalua-
tion of the intervention. The COACH Program, originally from Australia [12], was tested for
the first time in Europe and demonstrated a sustainable improvement in diabetes control. The
results of the randomized trial are reported elsewhere [13].
The objective was to analyze the lifelong cost-effectiveness of “The COACH Program”, a
nurse-led risk factor target-driven telephone self-management support program compared to
usual care, in people with type 2 diabetes in Belgium, from the perspective of the healthcare
system.
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Materials and Methods
Study design
AMarkov simulation model with a time horizon of 40 years was populated with patient-level
data from a 18-months randomized clinical trial in the Belgian primary care setting involving
574 type 2 diabetes patients [13]. Belgian guidelines for health economic evaluations were fol-
lowed in methodology and the Consolidated health economic evaluation reporting standards
(CHEERS) in reporting [14, 15].
Intervention
The COACH Program is a risk factor target-driven telephone counselling intervention deliv-
ered by diabetes nurse educators, who have followed a one-week training course. It consists of
five telephone sessions of 30 minutes on average, spread over 6 months, focused on achieving
guideline-recommendeddiabetes treatment targets through regular control of diabetes risk fac-
tors including self-monitoring of blood glucose, appropriate lifestyle adjustments and intensifi-
cation of medication therapy upon a consultation with the patient’s GP [13].
Comparator
The comparator was usual care. In Belgium, people with type 2 diabetes are treated by their
GPs. When insulin therapy needs to be initiated, the care team is extended by a certifieddiabe-
tes educator and endocrinologist.Patients with advanced diabetes, in need of three or more
insulin injections per day, are usually treated by an endocrinologist-ledhospital-based diabetes
team.
Patients
People between the ages of 18 and 75 diagnosedwith type 2 diabetes and on diabetes medica-
tion therapy were invited into the study by their health insurance fund based on the reimburse-
ment data of glucose-lowering agents in the preceding 12 months. Exclusion criteria comprised
patients on corticoid therapy and/or with a debilitating coexistingmedical condition such as
dialysis, mental illness, or cancer; residence in long-term care facilities; pregnancy; insufficient
proficiency in Dutch [13].
Study horizon
A lifetime prospectivemodeling was performedwith a time horizon of 40 years [16]. In addi-
tion, model predictions at time horizons between 1 and 40 years were explored.
Analytic perspective
The perspective of the Belgian health care system was applied. Direct health care costs to the
healthcare system including both the cost for the health insurance and the patient out-of-
pocket costs were included. Indirect and/or non-medical costs were not included in the analysis
[14].
Outcome Measures
Incremental cost-effectiveness ratio (ICER), Life Expectancy, Quality Adjusted Life Years
(QALYs) and cost of diabetes and its complications. These analyses were performed for the
entire cohort as well as for a subgroup of patients with inadequate glycemic control at baseline,
i.e. glycated hemoglobin (HbA1c)7%, in line with the clinical trial analysis [13].
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Modeling
The UKPDS OutcomeModel was applied for projecting effects observedwithin the clinical
trial over a life-time horizon. It models the occurrence of seven diabetes-related end points:
Ischemic Heart Disease (IHD), Myocardial infarction (MI), stroke, heart failure, amputation,
End-Stage Renal Disease (ESRD), blindness and death in people with type 2 diabetes to esti-
mate life expectancy, quality-adjusted life expectancy and costs. The model algorithms are
based on the observations of the UK Prospective Diabetes Study (UKPDS) participants who
were followed up for between six and twenty years [16]. The model uses an integrated system
of parametric equations and predicts the annual probability of any of the above end points by
using risk factors that include age, sex, ethnicity, duration of diabetes and history of diabetes-
related complications, height and weight, smoking status, total cholesterol, HDL cholesterol,
systolic blood pressure and HbA1c [17]. The model structure as well as the algorithms for the
sequence of events and the parametric equations used within the UKPDS OutcomeModel are
described in detail elsewhere [16]. The change in the modifiable risk factor values (smoking sta-
tus, total cholesterol, HDL cholesterol, systolic blood pressure and HbA1c) is modelled based
on the observationswithin the UKPDS study, by predicting the annual point estimates and the
associated 95% confidence intervals. The occurrence of events is predicted using Monte Carlo
methods [17].
The model has undergone internal and external validation [16]. Developed using data from
patients with newly-diagnosed type 2 diabetes, it generated results close to those observed in
clinical trials on patients in different stages of type 2 diabetes in a cross-validation exercise
[18]. The model is freely available for academic research, as a pre-programmed Excel 2010 file.
Clinical trial
The randomized clinical trial (RCT) underlying this economic evaluation enrolled 574 Dutch-
speaking independently living affiliates of the Flemish Independent Health Insurance Fund
“Partena”. Half of them (N = 287) were assigned to the intervention and the other half to the
control group. Their median age was 64 years; 62% were men; all were on glucose-lowering
medication therapy, of whom 14% on insulin or analogues. The average duration of type 2 dia-
betes was 7 years; 34% of patients had at least one comorbidity. The mean (SD) baseline
HbA1c was 7.0 (1.0) % in all participants and 7.9 (0.9) % in the subgroup with HbA1c7%
(further “elevated HbA1c subgroup”), Total Cholesterol: 176 (38) mg/dl, Blood Pressure: 133
(17)/75 (10) mmHg, BodyMass Index: 30 (5) kg/m2. All participants have followed a school
education, of whom 40% had completed primary, 39% secondary and 21% tertiary education
[19]; the majority (64%) were retired [13].
The primary outcome measure was the mean absolute change in HbA1c at 6 months in the
entire study group and the elevated HbA1c subgroup at baseline. Secondaryoutcomes were:
change in HbA1c at 18 months; change in total cholesterol, low-density lipoprotein, high-den-
sity lipoprotein, triglycerides, blood pressure, bodymass index, smoking status, self-perceived
health status, at 6 and 18 months’ follow-up.
At 6 months, the mean (95% CI) between-group difference in HbA1c change (%) was -0.2
(-0.3 to -0.1, P = .003) overall and -0.4 (-0.7 to -0.2, P = .001) in the elevated HbA1c subgroup,
in favor of the intervention. Other between-group differences in change were observed at 6
months in BMI (kg/m2): -0.4 (-0.6 to -0.1, P = .003) and TC (mg/dl): -6 (-11 to -1, P = .012). At
18 months’ follow-up, i.e. 12 months after the completion of the intervention, the improve-
ment in HbA1c was sustained: -0.2 (-0.3 to -0.0, P = .046) in the total sample and -0.4 (-0.7 to
-0.1, P = .023) in the elevated HbA1c subgroup. No other between-group differences were
observed at 6 and 18 months’ follow-up.
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Data input
Clinical data. The data collectedwithin the clinical trial were incorporated in the model
for each patient of both trial arms: age, sex, ethnicity, duration of diabetes, history of diabetes-
related complications, height and weight at baseline as well as smoking status, total cholesterol,
HDL cholesterol, systolic blood pressure and HbA1c outcomes at all three measurement points
(Tables 1 and 2).
Cost data. The mean annual total healthcare cost in diabetes patients without complica-
tions at baseline (95% CI) was €3,921 (3,216; 4,627). It was calculated as a mean of the sum of
the healthcare system costs and the legally imposed patient contributions in the subgroup of all
trial participants without self-reported comorbidities, in the year prior to the date of the ran-
domization. The claims database of the sickness funds was used as the data source.
The health care costs associated with each fatal or non-fatal diabetes-related complication
in the year of the event and in the subsequent years were collected from country-specificpub-
lished sources [20–27]. All costs were updated to 2013 Euros by using the Belgian health care
inflation rates [28] (Table 3).
Health utilities. The initial utility level, derived from self-reporting of the trial participants
using the EQ-5D 3-L questionnaire and calculated as overall sample mean at baseline based on
the Flemish utility value system, was 0.785 (0.765; 0.805) [14,29] and did not deviate from the
baseline utility level observedwithin UKPDS. Utility decrements for each of the seven diabe-
tes-related complications at time of event were adopted from the UKPDS OutcomeModel and
Table 1. Trial participants’ data incorporated in the UKPDS Model. Baseline characteristics.
Characteristic Intervention group (n = 287) Control group (n = 287)
Male, No (%) 173 (60) 180 (63)
Age, years: Median (range) 65.9 (35–75) 63.9 (35–75)
Diagnosis of type 2 diabetes since, No (%)
 2 years 46 (16) 41 (14)
 10 years 94 (33) 91 (32)
With one or more comorbidities (s), No (%) 92 (32) 103 (36)
Ischemic heart disease 35 (12) 39 (14)
Heart Failure 21 (7) 14 (5)
Myocardial infarction 11 (4) 13 (5)
Stroke 11 (4) 4 (1)
doi:10.1371/journal.pone.0163997.t001
Table 2. Trial participants’ data incorporated in the UKPDS Model. Risk factor outcomes at three measurement points.
Baseline Year 1 Year 2
Risk factor, Mean (SD) Intervention Control Intervention Control Intervention Control
HbA1C (%), all 7.0 (1.1) 7.0 (1.0) 6.8 (0.9) 7.0 (1.1) 6.9 (1.0) 7.0 (1.1)
HbA1c (%), subgroup 7.9 (1.0) 7.8 (0.8) 7.4 (0.9) 7.8 (1.1) 7.4 (1.0) 7.7 (1.2)
Weight (kg) 86.1 (16.9) 88.3(16.6) 84.8 (16.4) 87.0(15.9) 85.9 (16.6) 87.3 (15.4)
BMI (kg/m2)* 30.2 (4.9) 30.6 (5.2) 29.6 (4.9) 30.4 (5.1) 29.9 (5.0) 30.4 (5.1)
Total Cholesterol (mg/dl) 173 (37) 178 (39) 165 (36) 176 (39) 162 (34) 170 (49)
HDL-Cholesterol (mg/dl) 52 (16) 51 (14) 53 (15) 53 (16) 52 (15) 52 (15)
Systolic BP (mmHg) 133 (18) 132 (17) 128 (16) 130 (16) 128 (14) 130 (15)
Non-smokers (%) 85.7% 80.7% 87.8% 81.3% 88.6% 84.0%
*Height and weight were required only at baseline and not in the subsequent years.
doi:10.1371/journal.pone.0163997.t002
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in the subsequent years from other published research that used the same questionnaire, i.e.
EQ-5D 3-L and the UK utility value system [30–34] (Table 3).
Discounting future costs and outcomes
Future costs were discounted at 3.0%, future QALYs gained at 1.5% per annum [14].
Incremental costs of the intervention
The incremental cost of the intervention was calculated as sum of three components: 1) incre-
mental long-term costs forecasted with the UKPDS OutcomeModel, 2) incremental costs in
the year of the trial, and 3) costs of the intervention itself.
Within-trial incremental costs. At baseline, the annual mean total healthcare cost (CI)
was €5,543 (4,410–6,677) in the intervention and €4,101 (3,375–4,827) in the control group
and in the year of the trial €5,516 (4,630; 6,402) and €4,757 (3,892–5,622), implying a change
of -1% and +16% respectively (Table 4). This inverse trend was closely associated with the
change in hospitalization costs (R2 = .930, P< .001). As the observedopposite tendency in the
change in hospitalization costs (-18.5% in the intervention and +56% in the control group)
could have occurred by chance and/ or due to costly hospitalizations not associated with diabe-
tes, the incremental cost calculation was based on the change in the ambulatory costs. Indeed,
since the intervention is intended to optimize medical management, it was expected that costs
of ambulatory care in the intervention arm would increase during the year of the trial. Such an
increase was actually observed and comprised 9% in the intervention group compared to 4% in
the control group (Table 3). A more detailed analysis revealed a change in the intervention and
control group respectively, in the number of endocrinologist consultations: +35% and -10%
(P = .023), HbA1c tests: +9% and -12% (P< .001), lipid tests: +8% and -16% (P< .001) and
consumption of lipid modifying agents (measured in number of daily defined doses): +14%
and +1% (P< .001) [13].
Table 3. Data input in the UKPDS Outcome Model: Treatment costs of diabetes and complications and associated health utilities.
Fatal (acute) Non-fatal (at the time
of event, acute)
Cost in
subsequent years
Utility decrement at
diagnosis (event)
Utility decrement in
subsequent years
Ischemic heart disease (CHD) N.A. €10,976 [20] €6,044 [21] -0.09 [30] -0.046 [33]
Myocardial infarction €3,829[25;26] €7,989 [20] €6,044 [21] -0.055 [30] -0.032 [33]
Heart failure €10,416 [20] €10,416 [20] €7,431 [22] -0.108 [30] -0.05 [33]
Stroke €16,658 [22] €16,658 [22] €6,030 [21] -0.164 [30] -0.061 [33]
Diabetes-related foot amputation €46,387 [23] €46,387 [23] €781 [23] -0.280 [30] -0.13 [34]
Diabetes-related blindness N.A. €5,382 [24] 5,382 [24] -0.175 [30] -0.175 [31]
End stage renal disease 57,078 [25] 57,078 [25] 57,078 [25] -0.263 [31] -0.248 [33]
doi:10.1371/journal.pone.0163997.t003
Table 4. Ambulatory, hospital and total healthcare costs observed in each trial arm at baseline and in the year of the trial.
Healthcare costs Intervention group, Mean (CI) Control group, Mean (CI)
Year Baseline Trial Change Baseline Trial Change
Ambulatory 3,697(3,106; 4,288) 4,012(3,437; 4,587) +9.0% 3,148(2,804; 3,492) 3,271(2,909; 3,633) +4,0%
Hospital 1,846(1,067; 2,626) 1,504(992; 2,016) -18.5% 953(445–1,461) 1,486(878–2,094) +56.0%
Total 5,543(4,410; 6,677) 5,516(4,630; 6,402) -0.5% 4,101(3,375; 4,827) 4,757(3,892; 5,622) +16.0%
doi:10.1371/journal.pone.0163997.t004
An Economic Evaluation of a Nurse-Led Telecoaching Program in Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0163997 October 11, 2016 6 / 18
After a regression-based adjustment for the between-group difference in the ambulatory
costs at baseline [35], a within-trial ambulatory incremental intervention cost of €270 overall
and €179 in the elevated HbA1c subgroup was obtained (Table 5).
Costs of the intervention. The average operational program cost was €300.3 per patient
(Table 6). It consisted of the recruitment costs, fixed costs (software hosting and maintenance)
and variable costs (programmaterial: nutrition guide, a tape to measure waist circumference
and a set for self-monitoring of blood glucose; patient license fee; actual nurse time spent on
coaching and administration; telephone and mailing costs). All costs were registered prospec-
tively during the trial based on the individual time and material registration and the contractual
prices. The initial investment costs, such as a 5-day full time nurse training, program transla-
tion and technical set-up, are included in the uncertainty analysis and not in the base-case sce-
nario. Allocated to a limited number of patients, the investment costs would skew the per-
patient program costs, e.g. divided over 287 trial participants, they amount to €136.85 per
patient. However, if 10,000 patients are enrolled, the investment costs per participant decrease
to €3.93. Costs imposed by the study that are not part of routine practice, such as protocol-
driven nurse assessment visits and laboratory tests, were not included in the analysis.
Incremental effects of the intervention
Difference in Quality Adjusted Life Expectancybetween the intervention and control group
with associated 95% confidence intervals was calculated by the UKPDS OutcomesModel and a
Table 5. Calculation of the incremental within-trial healthcare costs associated with the intervention, in the entire cohort and the elevated HbA1c
subgroup.
Healthcare costs Total sample Elevated HbA1c subgroup
Group Intervention Control Intervention Control
Ambulatory annual healthcare costs, € (95% CI)
Trial year, baseline-adjusted* 3,777 (3,499; 4,054) 3,507 (3,304; 3,711) 3,768 (3,410; 4,125) 3,598 (3,310; 3,867)
Incremental intervention costs 270 (395; 343) N.A. 179 (100; 258) N.A.
*Regression based adjustment for the between-group difference in baseline costs on the observed data, equation: HCAdji2 ¼ HCi2   bðHCi1   HC1 Þ, with
i = 1,2 being the group indicator and β obtained from a regression of HC2 on HC1, being the health care cost in the year of the trial and at baseline,
respectively) [35]
doi:10.1371/journal.pone.0163997.t005
Table 6. Costs of the COACH Program.
Type of costs Total cost Costs per patient (N = 287)
Program set-up investment €39,275.0 €136.85
• Program management training €14,400.0
• Program translation €7,500.0
• Software configuration €8,800.0
• Training of the local coaches €8,575.0
Recruitment (mailing to 3115 patients and their GPs) €3,900.0 €13.6
Fixed costs (software hosting, per year) €3,790.0 €13.2
Variable costs €78,494.5 €273.5
• Welcome package €20.0
• Software license €50.0
• Nurse time (5.5 hours) €192.5
• Communication (telephone and mailing) €11.0
Total Program costs €86,184.5 €300.3
doi:10.1371/journal.pone.0163997.t006
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bootstrap simulation using 999 probability samples (the maximum number of bootstraps pro-
grammedwithin the model).
Incremental cost-effectiveness ratio
The ICER was calculated as a ratio between the mean incremental costs and the mean incre-
mental QALYs of the intervention group versus controls. The 95% confidence interval of the
ICER was calculated by using the upper and lower confidence levels of incremental costs and
utilities obtained with the probabilistic sensitivity analysis programmedwithin the UKPDS
OutcomesModel. In addition to the base-case 40 years’ time horizon, ICERs were calculated at
1, 2, 5 years and further at each 5-year interval.
Handling missing data and analysis of uncertainty
The RCT loss to follow-up at 6 and 18 months was 11% and 16% in the intervention group and
9% and 14% in the control group respectively (13). For the missing clinical data, a single impu-
tation technique was applied using Statistics Analysis System (SAS, version 9.2), i.e. for each of
the variables: smoking status, total cholesterol, HDL cholesterol, systolic blood pressure,
HbA1c, age and diabetes duration, the mean value was imputed conditional on the other
observedvalues, assuming a multivariate normal distribution. There were no missing claims
data.
The parameter—and methodological uncertainty was handled by one-way sensitivity analy-
sis and presented in a Tornado diagram illustrating the impact of different scenarios on the
value of ICER. The following scenarios were explored: 1) the program costs varied by 50%; 2)
the costs of complications varied by 50%; 3) the upper and lower confidence levels of utility
decrements; 4) discount rates for costs and effects set to 0% and to 5%; 5) the effect of the inter-
vention disappearing beyond 18 months, or staying unchanged for lifetime; 6) the intervention
repeating bi-annually for 20 years, to sustain the achieved effect.
Results
In the basecase scenario analysis of the entire cohort data, the UKPDS OutcomesModel (fur-
ther “Model”) calculated a mean Life Expectancy (95% CI) of 10.52 (9.61; 11.44) years in the
intervention group versus 10.26 (9.36; 11.16) in the control group, corresponding with Quality
Adjusted Life Expectancyof 8.04 (7.36; 8.71) versus 7.83 (7.17; 8.49) respectively and implying
0.21 (0.13; 0.28) QALYs gained with the COACH Program. At 40 years’ horizon, the Model
forecasted a cumulative decrease in the event rate in the intervention group by 0.2% for IHD,
0.9% for MI, 1.3% for heart failure, 0.8% for stroke and 0.3% for all-cause death (Table 7). The
long-term treatment cost of diabetes and complications computed by the Model was respec-
tively €57,226 (50,408; 64,044) and €56,649 (49,939; 63,358). After adding the incremental
within-trial costs and the cost of the intervention, the mean total incremental long-term cost in
the intervention group was €1,147 (188; 2,107). The mean ICER (95% CI) was €5,569 per
QALY (€677; €15,679), with a 2.0% probability that the intervention is cost-saving and a 98.2%
probability that the ICER lies below the threshold of €10,000 per QALY (Figs 1 and 2).
In the elevated HbA1c subgroup, the Model predicted a Life Expectancyof 10.05 (9.15;
10.96) in the intervention and 9.33 (8.47; 10.19) in the control group and the Quality Adjusted
Life Expectancyof 7.66 (6.99; 8.33) and 7.10 (6.47; 7.74) respectively, meaning a QALY gain of
0.56 (0.43; 0.68) achieved with The COACH Program. The modeled long-term treatment costs
were €55,876 (48,947; 62,805) in the intervention and €53,855 (47,095; 60,614) in the control
group, resulting in an incremental total long-term cost of €2,565 (654; 4,474) and an ICER of
€4,615 (1,207; 9,969). The probability that the intervention would be cost-saving in people with
An Economic Evaluation of a Nurse-Led Telecoaching Program in Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0163997 October 11, 2016 8 / 18
poorly controlled HbA1c was 0.3%, while the chance that the ICER lies below the threshold of
€10,000 per QALY equaled 100% (Figs 1 and 2).
An inverse relationship was observedbetween the ICER values and the applied time horizon
in the entire cohort, with €811,250 per QALY in the first year after the program delivery and a
steep fall to €84,455 in year five; €30,868 in year ten; €9,880 and €6,212 in year twenty and
Table 7. Cumulative event rates from modeling simulation at 5, 10, 20, 30 and 40 years, %.
Complications Year Intervention group Control group Difference (I-C)
Entire cohort Subgroup Entire cohort Subgroup Entire cohort Subgroup
Ischemic heart disease 5 1.93 2.13 2.20 2.45 -0.28 -0.32
10 4.00 4.48 4.51 4.99 -0.51 -0.51
20 6.57 7.00 6.90 7.30 -0.33 -0.31
30 7.23 7.62 7.47 7.63 -0.24 -0.01
40 7.35 7.79 7.52 7.72 -0.17 0.07
Myocardial infarction 5 11.40 13.16 11.42 12.76 -0.02 0.40
10 19.88 22.07 20.25 21.18 -0.38 0.89
20 28.20 30.05 29.21 29.55 -1.01 0.51
30 30.09 32.12 31.08 30.88 -0.99 1.25
40 30.41 32.46 31.29 30.95 -0.88 1.52
Heart failure 5 3.65 3.98 4.15 4.69 -0.50 -0.71
10 7.20 7.56 7.99 8.73 -0.79 -1.17
20 11.39 11.97 12.62 13.17 -1.23 -1.20
30 12.30 13.03 13.62 13.98 -1.32 -0.95
40 12.45 13.17 13.73 14.01 -1.28 -0.84
Stroke 5 4.64 5.25 5.06 5.57 -0.42 -0.32
10 8.63 9.25 9.17 9.99 -0.54 -0.75
20 12.81 13.38 13.57 14.29 -0.76 -0.90
30 13.70 14.23 14.53 15.05 -0.83 -0.82
40 13.79 14.32 14.61 15.08 -0.82 -0.76
Amputation 5 0.32 0.36 0.28 0.44 0.03 -0.08
10 0.75 1.02 0.70 0.95 0.05 0.07
20 1.53 1.86 1.52 1.82 0.02 0.04
30 1.86 2.21 1.78 2.10 0.08 0.10
40 1.93 2.24 1.84 2.13 0.09 0.11
Blindness 5 2.46 2.88 2.56 2.70 -0.09 0.17
10 4.51 4.46 4.56 4.67 -0.06 -0.21
20 6.48 6.15 6.56 6.71 -0.08 -0.57
30 6.92 6.52 6.98 7.06 -0.06 -0.55
40 6.95 6.58 7.02 7.12 -0.07 -0.54
Renal Failure 5 0.23 0.28 0.24 0.25 -0.01 0.03
10 0.62 0.60 0.59 0.63 0.03 -0.03
20 1.18 1.18 1.15 1.11 0.03 0.08
30 1.41 1.44 1.40 1.30 0.01 0.14
40 1.47 1.55 1.45 1.30 0.02 0.25
All cause death 5 27.05 30.10 27.62 31.41 -0.56 -1.32
10 48.94 52.74 49.43 54.11 -0.50 -1.37
20 81.60 82.67 82.51 86.73 -0.92 -4.07
30 95.39 94.90 96.73 98.36 -1.35 -3.46
40 99.51 99.45 99.81 99.98 -0.30 -0.52
doi:10.1371/journal.pone.0163997.t007
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Fig 1. Cost-effectiveness plane based on 999 bootstraps of costs and QALYs. Bootstrapping results of the entire cohort and the elevated HbA1c
subgroup, base-case analysis with 40 years’ time horizon.
doi:10.1371/journal.pone.0163997.g001
Fig 2. Cost-effectiveness acceptability curves for the COACH Program based on the Monte Carlo simulation of data from the entire cohort
and the subgroup with poorly controlled HbA1c at baseline. Baseline analysis with 40 years’ time horizon.
doi:10.1371/journal.pone.0163997.g002
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thirty respectively. In the elevated HbA1c subgroup, the ICER was €52,680 per QALY in the
first year after the trial, €10,201 in the second year, and did not exceed the value of the 40-time
horizon, at any of the other simulated years (Fig 3).
The one-way sensitivity analysis demonstrated a lifetime QALY gain in the intervention
group in all applied scenarios, with a variability of the ICER between €4,168 and €13,034 per
QALY in the entire cohort and between €2,629 and €7,858 per QALY in the elevated HbA1c
subgroup. Assuming that the effect of the intervention disappeared after 18 months, the calcu-
lations showed a mean incremental QALY of 0.14 in the entire cohort and 0.53 in the elevated
HbA1c subgroup, with the respective ICERs of €4,556 and €3,336 per QALY. Assuming that
the effect stayed unchanged for life, the QALY gained with telecoachingwere 0.32 and 0.67,
and the ICERs €5,198 and €5,586 per QALY, respectively. The hypothesis that the intervention
needs to be repeated bi-annually for life, to sustain the achieved effect, had the greatest impact
on the cost-effectiveness, followed by varying the cost of diabetes complications (Figs 4 and 5).
Discussion
The cost-effectiveness analysis of The COACH Program adapted to the Belgian primary care
setting and performed by populating the UKPDS OutcomesModel with the data of the ran-
domized clinical trial participants, showed a mean QALY gain of 0.21 in the entire cohort and
0.56 in the subgroup with poorly controlled HbA1c at baseline. The mean ICER in the respec-
tive study cohorts was €5,569 and €4,615 per QALY, with 2.0% and 0.3% respective probabili-
ties for telecoaching to be cost-saving and 98.2% and 100% probabilities that the value of ICER
lies below the threshold of €10,000 per QALY. In the intervention group, a gain in QALYs was
demonstrated in all scenarios and was associated with a greater/ longer healthcare utilization.
The assumption that the telecoaching program needs to be repeated bi-annually for life, to
Fig 3. ICER of The COACH Program as a function of the applied time horizon. Results for the entire cohort and the elevated HbA1c subgroup.
doi:10.1371/journal.pone.0163997.g003
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Fig 4. One-Way Sensitivity Analysis showing the influence of changing different parameters on the long-term cost-effectiveness in the entire
cohort.
doi:10.1371/journal.pone.0163997.g004
Fig 5. One-Way Sensitivity Analysis showing the influence of changing different parameters on the long-term cost-effectiveness in the
subgroup with poorly controlled HbA1c at baseline.
doi:10.1371/journal.pone.0163997.g005
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sustain the achieved effect, had the greatest impact on the ICER: €13,034 and €7,858 in the
entire cohort and the elevated HbA1c subgroup respectively.
Though the application of a single ICER threshold in the national reimbursement decisions
is not common [36], the World Health Organization recommends considering health technol-
ogies with the ICER below the value of the gross domestic product (GDP) per capita as very
cost-effective [37]. With the GDP above €43,000 [38], the target-driven nurse-led telecoaching
of people with type 2 diabetes has great potential to be considered cost-effectivewithin the Bel-
gian healthcare system.
The results are comparable with those obtained in the cost-effectiveness study of diabetes
group education in the UK, where a lifetime prediction with the Sheffield diabetes model was
applied and the ICER of £5,387 (€6,700) per QALY was reported [39]. No other similar Euro-
pean studies were identified. Several published economic evaluations applied a short-term ana-
lytic horizon, which complicated interpretation of the results [40–42]. The meaningfulness of
short-term cost-effectiveness analysis of diabetes self-management programs is questionable,
as it has been shown that the greatest costs occur in the year of the delivery and decrease in sub-
sequent years, while most of the benefits occur after several years of follow-up [43]. The analy-
sis of ICER in the entire cohort at different time points confirmed this observation, showing a
consistent improvement in the cost-effectiveness over time. A key question for policymakers
therefore is whether they are prepared to consider a longer term horizon in their decision-mak-
ing [44].
While the study aimed to assess the long-term cost-effectiveness, the results of the within-
trial analysis deserve attention. Though participants of the telecoaching program demonstrated
an increase in utilization of the guideline-recommendedambulatory diabetes care, the overall
healthcare costs in the year of the trial decreased by 1% in the intervention group. The control
group showed the opposite trend: a decrease in the guideline-recommendedcare consumption
and an increase in overall healthcare costs by 16%. Change in total costs in both groups was
strongly associated with hospitalization costs; however, it was difficult to attribute these
changes to the intervention due to a lack of insight into the admission causes. Diabetes educa-
tion has previously been shown to have a positive impact on the number of hospital admissions
in the short to medium term, based on retrospective studies [45,46],—a hypothesis that
requires further testing in a randomized setting.
Every health economicmodel has its limitations. Differences between patient baseline char-
acteristics and the clinical setting underlying the model, and those used to populate the model,
may result in varying long-term disease progression patterns [47]. However, given the scarcity
of appropriate data and resources, it is not feasible to develop newmodels specific to each set-
ting [48]. From at least thirteen available predictive diabetes models, the UKPDS Outcomes
Model has undergone the most extensive external validation of its ability to predict the inci-
dence of cardiovascular disease through a comparison with the results of large cohort studies
in people with type 2 diabetes. It has been shown to consequently overestimate the risk of coro-
nary heart disease and stroke [48–52]. The Model should therefore be used with caution for the
prediction of the absolute risk of diabetes complications, but is believed to provide a reasonable
prediction of the incremental event rate and be a suitable method for resource prioritization
[50–52]. The Model performance in estimating the risk of microvascular complications should
be further investigated. Introduction of electronic patient records at the national level and their
structural use in epidemiological research should be of great importance for the development
of well-performingmodels in different patient subgroups. Recently, the second version of the
UKPDS OutcomesModel was released; however, the validation of its equations is still ongoing
[53].
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Until now, most nurse-led telecoaching programs have been unsuccessful in improving glyce-
mic control, even though the recruited patients had an elevated HbA1c at baseline [54–56]. The
COACH Program implemented in the Belgian primary care setting resulted in a clinically mod-
est HbA1c reduction by 0.2% in the total sample and a clinically significant reduction by 0.4% in
the subgroup of patients with HbA1c7% at baseline, sustainably lowering the mean HbA1c in
the intervention group to the recommended target below 7%. In addition, clinically modest
improvements in BMI and Total Cholesterol were observedat 6 months’ follow-up. A compara-
ble effect on the glycemic control was achieved with face-to-face and group education programs;
however, it was limited to the subgroups with HbA1c 8% at baseline [5], and tended to disap-
pear within one to three months after the completion of the intervention [6]. The concept of the
COACH Program therefore merits special attention. In the past 15 years the COACH Program
has proved effective in different conditions and settings [12,13,57]. The critical success factors of
the program, and tailored session content focused on patient empowerment; goal-setting and
negotiation of an action plan that includes appropriate medical visits, lifestyle adjustments and
medication adherence, quality assurance measures and a constructive interaction with the
involved physicians, have to be considered in the implementation phase [13].
Limitations to the overall generalizability of the study results include possible positive self-
selection of patients recruited into the study, exclusion of people with debilitatingmedical condi-
tions and the Belgian-specificcultural, organizational and economic context. However, consider-
ing a fair heterogeneity of the study population and the pragmatic nature of the clinical trial, the
results of the study are potentially transferrable to primary care settings inWestern countries.
The baseline characteristics of the trial participants were comparable to those of the general Bel-
gian population with type 2 diabetes in terms of clinical, biomedical and demographic data
[58,59]. Moreover, a similar clinical effect was achieved with The COACH Program in patients
with type 2 diabetes in different cultural contexts [13,57]. Further research should identify those
groups of patients whomight benefit from diabetes education through alternative delivery
modes. Socially disadvantaged people and those with limited language skills may present partic-
ular challenges to goal-based care and require more intensive modes of support [13].
More economic evaluations of healthcare programs are needed to support the policymakers
in their decisions on budget allocation. Currently, patient self-management support programs
are structurally underfinanced,while relevant health economic research is strongly underrepre-
sented compared to evaluations of medicines.However, the results of the cost-effectiveness
analyses are not the only criterion worth considering whenmaking reimbursement decisions
[60]. Severity of disease, size of the target population, budget impact, and availability of treat-
ment alternatives may also play a role alongside legal, ethical and organizational issues [61]. At
present, reimbursement decisions in healthcare frequently lack a systematic approach [62].
Policy tools such as priority setting and multi-criteria decision-making are being explored and
have the potential to increase the transparency of reimbursement decisions [60, 63–65].
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